Ani Pharmaceuticals

Ani Pharmaceuticals

ANIP· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +42.8% in FY2025

Nikhil Lalwani is the CEO of Ani Pharmaceuticals and was paid $10.3M in FY2025 (Dec), up 16%.

Pay$100 in the stock at the end of FY20 → $272
CEO pay is from each Ani Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Nikhil LalwaniFY2025
  2. 2Christopher K. MutzFY2025
  3. 3Stephen P. CareyFY2025
  4. 4Meredith W. CookFY2025
  5. 5Ori GutwergFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Ani Pharmaceuticals paid its 5 named executives $21.6M in total in FY2025 (Dec). CEO Nikhil Lalwani was paid $10.3M of that.

Name
Nikhil LalwaniPresident and Chief Executive Officer
Christopher K. MutzSenior Vice President, Head of Rare Disease
Stephen P. CareySenior Vice President, Finance and Chief Financial Officer
Meredith W. CookSenior Vice President, General Counsel and Corporate SecretaryNot disclosed
Ori GutwergSenior Vice President, Generics

of each named executive, from the Summary Compensation Table of each proxy.

Peers17

See all

The FY2025 (Dec) proxy of Ani Pharmaceuticals names 17 peer companies for pay. Pay versus performance data of Ani Pharmaceuticals for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board1

See all
  • Nikhil LalwaniDirector · 5 yr on the boardNot independent—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Ani Pharmaceuticals CFO pay rose 14% to $3.3M. The stock rose 43% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Ani Pharmaceuticals CEO pay rose 16% to $10.3M. The stock rose 43% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Ani Pharmaceuticals General counsel pay rose 15% to $2.3M. The stock rose 43% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Ani Pharmaceuticals Division head pay rose 40% to $3.4M. The stock rose 43% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Ani Pharmaceuticals CFO pay rose 11% to $2.9M. The stock did not change in FY2024 (Dec).
    DEF 14A
  6. Pay
    Ani Pharmaceuticals Division head pay rose 26% to $2.4M. The stock did not change in FY2024 (Dec).
    DEF 14A
  7. Pay
    Ani Pharmaceuticals CFO pay rose 26% to $2.6M. The stock rose 37% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Ani Pharmaceuticals CFO pay fell 28% to $2.0M. The stock fell 13% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Ani Pharmaceuticals Division head pay rose 42% to $1.9M. The stock rose 37% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Ani Pharmaceuticals Division head pay fell 10% to $1.4M. The stock fell 13% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Ani Pharmaceuticals CEO pay rose 58% to $8.1M. The stock rose 37% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Ani Pharmaceuticals CEO pay fell 22% to $5.1M. The stock fell 13% in FY2022 (Dec).
    DEF 14A
  13. Pay
    Ani Pharmaceuticals Division head pay rose 47% to $1.9M. The stock rose 37% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Ani Pharmaceuticals Division head pay fell 19% to $1.3M. The stock fell 13% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 9, 2026FY2025
Annual report10-KFeb 27, 2026FY2025
Proxy statementDEF 14AApr 10, 2025FY2024
Annual report10-KFeb 28, 2025FY2024
Proxy statementDEF 14AApr 5, 2024FY2023
Annual report10-KFeb 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data